MantaBio
Private Company
Total funding raised: $23.2M
Overview
MantaBio is a private, pre-revenue synthetic biology company founded in 2020 and based in San Diego, CA. It is developing the MantaVision System, a fully automated, single-use molecular diagnostics platform for rapid microbial contamination testing, targeting the biopharmaceutical manufacturing and veterinary diagnostics markets. Led by a founder with deep expertise in pathogen detection and digital PCR, the company aims to revolutionize microbial testing by delivering results in two hours versus the days or weeks required by traditional culture methods.
Technology Platform
MantaVision System: A fully automated, single-use, cartridge-based platform for rapid molecular detection of viable microorganisms using advanced genetic testing (likely leveraging digital PCR). Designed for at-line or lab use with a 2-hour turnaround.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
MantaBio competes with other companies developing Rapid Microbiological Methods (RMM), which may include technologies like ATP bioluminescence, flow cytometry, and nucleic acid amplification. It also competes indirectly with the entrenched culture-based methods and large diagnostic firms that may have their own RMM offerings. Its differentiation lies in full automation, viability detection, and a 2-hour claim.